Objective: To investigate the effects of laparoscopic radical surgery on the treatment of colorectal cancer (CRC) and explore the correlations of vascular endothelial growth factor (VEGF) and transforming growth factor-β1 (TGF-β1) with prognosis.
Methods: The clinical data of 210 patients with CRC admitted to the Yantai Zhifu Hospital from February 2015 to February 2018 were analyzed retrospectively. Among them, 110 patients were treated with laparoscopic radical surgery and assigned to the observation group, and the rest 100 patients were treated with routine open surgery and included in the open group. The two groups were compared in terms of operation time (OT), intraoperative blood loss (IBL), postoperative exhaust time (PET), length of hospital stays (LOS) and incidence of complications. Patients were also followed up for 3 years to count their survival rates. Serum expression levels of VEGF and TGF-β1, detected by enzyme-linked immunosorbent assays (ELISAs), were compared before and after treatment, and their correlations with patients' clinicopathological data and prognosis were analyzed.
Results: Compared with the open group, patients in the observation group had longer OT, but lower IBL, PET, LOS, and overall incidence of complications. In the observation group, VEGF and TGF-β1 expression after treatment was remarkably lower than that before treatment and that in the open group. A 3-year survival rate of 80.0% was observed in the observation group. Univariate analysis showed that serum VEGF and TGF-β1 expression levels were closely related to Dukes staging and lymph node metastasis (LNM) (<0.05). The Log-Rank test showed that the survival rate of patients with high VEGF and TGF-β1 expression was remarkably lower than that of those with low expression (<0.05). According to Cox model multivariate analysis, Dukes staging, LNM, surgical methods and high VEGF and TGF-β1 expression were all independent risk factors for the prognosis of CRC patients (<0.05).
Conclusion: Laparoscopic radical surgery is effective and safe in treating CRC. VEGF and TGF-β1 are highly expressed in the serum of CRC patients, and are closely related to the tumor staging, LNM and prognosis of patients, which are of great significance for evaluating the condition and prognosis of CRC patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661244 | PMC |
BMC Complement Med Ther
December 2024
Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Background: A precise observation is that the cervix's solid tumors possess hypoxic regions where the oxygen concentration drops below 1.5%. Hypoxia negatively impacts the host's immune system and significantly diminishes the effectiveness of several treatments, including radiotherapy and chemotherapy.
View Article and Find Full Text PDFReprod Toxicol
December 2024
Department of Comparative Biosciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI, USA; Department of Obstetrics and Gynecology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA. Electronic address:
Per- and polyfluoroalkyl substances (PFAS) are linked to preeclampsia (PE), a condition involving abnormal angiogenesis. Prior research on this association has been inconclusive. We investigated the relationship between maternal PFAS exposure and PE risk in Wisconsin.
View Article and Find Full Text PDFNat Prod Res
December 2024
Department of Zoology, GC University, Lahore, Pakistan.
Inhibiting angiogenesis with plant-derived bioactive compounds can inhibit tumour progression. Antiangiogenic potential of was analysed by preparing and analysing ethanolic extracts of by GC-MS and HPLC to identify bioactive components. In-vivo blood vessel formation assays in mice and chorioallantoic membrane assays (CAM) in eggs were employed to assess the antiangiogenic effects.
View Article and Find Full Text PDFClin Exp Ophthalmol
December 2024
The Save Sight Institute, Sydney Medical School, the University of Sydney, Sydney, New South Wales, Australia.
Background: We aimed to describe a 2-year outcome of eyes managed by practitioners benchmarked using a funnel plot by their frequency of treatment using vascular endothelial growth factor (VEGF) inhibitors for naive retinal vein occlusion (RVO).
Methods: A multicentre, international, observational study of 29 doctors in 12 countries managing 1110 eyes with RVO commencing VEGF inhibitors between 1 January 2012-2022 tracked in the Fight Retinal Blindness! registry.
Results: We identified 3 outlying 'intensive' practitioners (managing 350/1110 eyes [32%]), 22 'typical' practitioners (604/1110, [54%]) and 4 outlying 'relaxed' practitioners (156/1110, [14%]) with respective 24-month outcomes in Branch and Central RVO including the primary outcome, mean adjusted change in visual acuity (VA) in BRVO: +16.
The introduction of faricimab, a drug targeting both vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2, has enabled the implementation of the highly effective dual inhibition strategy in real clinical practice for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), both previously treated with intravitreal injections and newly diagnosed. This article presents a series of 11 clinical cases involving patients with nAMD and DME who received loading doses of faricimab and continued ophthalmological observation. Among them, three patients with nAMD and two with DME were treatment-naïve, while the others were switched from alternative therapies to faricimab.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!